"Benzhydryl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed.
| Descriptor ID |
D001559
|
| MeSH Number(s) |
D02.455.426.559.389.115
|
| Concept/Terms |
Benzhydryl Compounds- Benzhydryl Compounds
- Compounds, Benzhydryl
- Diphenylmethyl Compounds
- Compounds, Diphenylmethyl
|
Below are MeSH descriptors whose meaning is more general than "Benzhydryl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Benzhydryl Compounds".
This graph shows the total number of publications written about "Benzhydryl Compounds" by people in this website by year, and whether "Benzhydryl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 2 | 5 |
| 2006 | 0 | 1 | 1 |
| 2008 | 3 | 0 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 3 | 1 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 5 | 3 | 8 |
| 2015 | 2 | 0 | 2 |
| 2016 | 5 | 0 | 5 |
| 2017 | 2 | 2 | 4 |
| 2018 | 2 | 0 | 2 |
| 2019 | 3 | 1 | 4 |
| 2020 | 3 | 2 | 5 |
| 2021 | 2 | 3 | 5 |
| 2023 | 1 | 2 | 3 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzhydryl Compounds" by people in Profiles.
-
Acute Hemodynamic Effects of Empagliflozin: Are They Relevant to the Clinical Practice? Cardiovasc Drugs Ther. 2024 Aug; 38(4):769-770.
-
The national financial burden of guideline directed medical therapy for heart failure patients from 2013 to 2021. Curr Probl Cardiol. 2024 Aug; 49(8):102684.
-
Dapagliflozin for Atrial Fibrillation. Cardiovasc Drugs Ther. 2024 Feb; 38(1):1-3.
-
Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation. Curr Opin Pharmacol. 2023 12; 73:102415.
-
Effects of developmental exposures to Bisphenol-A and Bisphenol-S on hepatocellular function in male Long-Evans rats. Life Sci. 2023 Aug 01; 326:121752.
-
Sex-specific associations between urinary bisphenols concentrations during pregnancy and problematic child behaviors at age 2?years. Neurotoxicol Teratol. 2023 Mar-Apr; 96:107152.
-
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 11; 27(11):1954-1960.
-
Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus. Cardiovasc Drugs Ther. 2022 10; 36(5):829-840.
-
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. Diabetes Obes Metab. 2021 06; 23(6):1426-1430.
-
Early eGFR decline after SGLT2i initiation: knowns and unknowns. Kidney Int. 2021 03; 99(3):548-550.